GlassScriptPhysician profile
Alan Varraux
NPI 1841392263
$1,679.16
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $379 · 2021: $316 · 2022: $430 · 2023: $24.61 · 2024: $16.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.61 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.61 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $511.85 | 2019-2022 | |
| Genentech USA, INC. | $364.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $210.51 | 2019-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.60 | 2019-2020 | |
| Mylan Specialty L.P. | $90.28 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $87.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.97 | 2019-2021 | |
| Genzyme Corporation | $60.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.56 | 2020 | |
| Insmed, INC. | $32.48 | 2022-2024 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $26.78 | 2021 | |
| Pfizer INC. | $15.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Varraux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.